Delving into the Latest Updates on Shanghai HOB Biological Medicine Co., Ltd. with Synapse

Overview

Tags

Otorhinolaryngologic Diseases

Immune System Diseases

Respiratory Diseases

Allergen extract

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Allergen extract	1

[Translation] A prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate the efficacy and safety of sublingual immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without mild to moderate asthma and allergy to house dust mites and/or dust mites

主要目的是评估30,000 TU/mL剂量的MM09舌下给药相较安慰剂治疗12个月在12-65岁伴或不伴轻至中度受控的间歇性或持续性哮喘（根据GINA的定义）、对屋尘螨和/或粉尘螨过敏的中至重度鼻炎/鼻结膜炎（根据ARIA分类）受试者中的有效性。

[Translation]

The primary objective was to evaluate the efficacy of MM09 sublingually at a dose of 30,000 TU/mL compared to placebo for 12 months in subjects aged 12-65 years with mild to moderate controlled intermittent or persistent asthma (as defined by GINA) or moderate to severe rhinitis/rhinoconjunctivitis (as classified by ARIA) who were allergic to house dust mites and/or dust mites.

Start Date-

Sponsor / Collaborator

Shanghai HOB Biological Medicine Co., Ltd.

[+1]

100 Clinical Results associated with Shanghai HOB Biological Medicine Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai HOB Biological Medicine Co., Ltd.

Login to view more data

100 Deals associated with Shanghai HOB Biological Medicine Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai HOB Biological Medicine Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data